Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Cilie W. Hansen"'
Publikováno v:
Clinical Pharmacokinetics
Background Oral semaglutide is a tablet co-formulation of the human glucagon-like peptide-1 (GLP-1) analog semaglutide with the absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). The absorption of coadministered oral drugs ma
Publikováno v:
Expert Opinion on Drug Metabolism & Toxicology. 14:869-877
Since the first oral glucagon-like peptide-1 analog comprises semaglutide co-formulated with an absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate, which induces a transient, localized increase in gastric pH, we have investigated wh
Publikováno v:
Journal of Clinical Pharmacology
Semaglutide is a human glucagon‐like peptide‐1 analog that has been co‐formulated with the absorption enhancer, sodium N‐(8‐[2‐hydroxybenzoyl] amino) caprylate, for oral administration. This trial ({"type":"clinical-trial","attrs":{"text"
Autor:
Erik Christiansen, Astrid Breitschaft, Cilie W. Hansen, Tine A. Bækdal, Charlotte Granhall, Andreas Børsting Jordy, Azadeh Houshmand-Oregaard
Publikováno v:
Diabetes. 67
Semaglutide is a glucagon-like peptide (GLP-1) analog co-formulated with the absorption enhancer, sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC), to allow oral administration. The effect of oral semaglutide on the pharmacokinetics (PK) of the